SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
148 hedge funds and large institutions have $820M invested in SANGAMO THERAPEUTICS INC in 2017 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 38 reducing their positions, and 23 closing their positions.
76% more capital invested
Capital invested by funds: $467M → $820M (+$353M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
42% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 38
34% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $15.8M
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
3% more funds holding
Funds holding: 143 → 148 (+5)
8.36% less ownership
Funds ownership: 73.73% → 65.37% (-8.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$14.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.6M |
| 3 |
BlackRock
New York
|
+$12.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$25.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$22.1M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$19.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.84M |
SGMO Hedge Fund Activity: Q3 2017 in Review
148 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2017, worth a combined $820M — up 76% from $467M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SGMO positions and 23 closed out — a net gain of 6 holders — while 54 added to existing stakes and 38 trimmed.
The largest buyer was Invesco, adding an estimated $14.6M. The largest seller was EcoR1 Capital, cutting an estimated $25.9M.
- 148 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2017, up from 143 in Q2 2017.
- Funds reported $820M of SANGAMO THERAPEUTICS INC stock for Q3 2017, up 76% quarter-over-quarter.
- 29 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2017 and 23 closed out, a net change of +6 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2017 was Invesco, an estimated $14.6M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2017 was EcoR1 Capital, an estimated $25.9M sold.
Based on aggregated 13F filings for Q3 2017.